These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 21275080)

  • 1. 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia.
    Condray R; Dougherty GG; Keshavan MS; Reddy RD; Haas GL; Montrose DM; Matson WR; McEvoy J; Kaddurah-Daouk R; Yao JK
    Int J Neuropsychopharmacol; 2011 Jul; 14(6):756-67. PubMed ID: 21275080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients.
    Myint AM; Schwarz MJ; Verkerk R; Mueller HH; Zach J; Scharpé S; Steinbusch HW; Leonard BE; Kim YK
    Brain Behav Immun; 2011 Nov; 25(8):1576-81. PubMed ID: 21620952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia.
    Yao JK; Dougherty GG; Reddy RD; Keshavan MS; Montrose DM; Matson WR; Rozen S; Krishnan RR; McEvoy J; Kaddurah-Daouk R
    Mol Psychiatry; 2010 Sep; 15(9):938-53. PubMed ID: 19401681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune and Neuroendocrine Trait and State Markers in Psychotic Illness: Decreased Kynurenines Marking Psychotic Exacerbations.
    De Picker L; Fransen E; Coppens V; Timmers M; de Boer P; Oberacher H; Fuchs D; Verkerk R; Sabbe B; Morrens M
    Front Immunol; 2019; 10():2971. PubMed ID: 32010121
    [No Abstract]   [Full Text] [Related]  

  • 5. Decreased plasma tryptophan and tryptophan/large neutral amino acid ratio in patients with neuroleptic-resistant schizophrenia: relationship to plasma cortisol concentration.
    Lee M; Jayathilake K; Dai J; Meltzer HY
    Psychiatry Res; 2011 Feb; 185(3):328-33. PubMed ID: 20699195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum xanthurenic acid levels: Reduced in subjects at ultra high risk for psychosis.
    Curto M; Lionetto L; Fazio F; Corigliano V; Comparelli A; Ferracuti S; Simmaco M; Nicoletti F; Baldessarini RJ
    Schizophr Res; 2019 Jun; 208():465-466. PubMed ID: 30837204
    [No Abstract]   [Full Text] [Related]  

  • 7. Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders.
    Steen NE; Dieset I; Hope S; Vedal TSJ; Smeland OB; Matson W; Kaddurah-Daouk R; Agartz I; Melle I; Djurovic S; Jönsson EG; Bogdanov M; Andreassen OA
    Psychol Med; 2020 Mar; 50(4):595-606. PubMed ID: 30867076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations of Kynurenic Acid, 3-Hydroxykynurenine, sIL-2R, IFN-α, and IL-4 with Clinical Symptoms During Acute Relapse of Schizophrenia.
    Szymona K; Zdzisińska B; Karakuła-Juchnowicz H; Kocki T; Kandefer-Szerszeń M; Flis M; Rosa W; Urbańska EM
    Neurotox Res; 2017 Jul; 32(1):17-26. PubMed ID: 28275903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum kynurenic acid is reduced in affective psychosis.
    Wurfel BE; Drevets WC; Bliss SA; McMillin JR; Suzuki H; Ford BN; Morris HM; Teague TK; Dantzer R; Savitz JB
    Transl Psychiatry; 2017 May; 7(5):e1115. PubMed ID: 28463241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients.
    Schwieler L; Samuelsson M; Frye MA; Bhat M; Schuppe-Koistinen I; Jungholm O; Johansson AG; Landén M; Sellgren CM; Erhardt S
    J Neuroinflammation; 2016 Feb; 13(1):51. PubMed ID: 26925576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tryptophan pathway alterations in the postpartum period and in acute postpartum psychosis and depression.
    Veen C; Myint AM; Burgerhout KM; Schwarz MJ; Schütze G; Kushner SA; Hoogendijk WJ; Drexhage HA; Bergink V
    J Affect Disord; 2016 Jan; 189():298-305. PubMed ID: 26454336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of electroconvulsive therapy on the tryptophan-kynurenine metabolic pathway.
    Guloksuz S; Arts B; Walter S; Drukker M; Rodriguez L; Myint AM; Schwarz MJ; Ponds R; van Os J; Kenis G; Rutten BP
    Brain Behav Immun; 2015 Aug; 48():48-52. PubMed ID: 25765557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
    Meier TB; Drevets WC; Wurfel BE; Ford BN; Morris HM; Victor TA; Bodurka J; Teague TK; Dantzer R; Savitz J
    Brain Behav Immun; 2016 Mar; 53():39-48. PubMed ID: 26546831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The kynurenic acid hypothesis - a new look at etiopathogenesis and treatment of schizophrenia].
    Flis M; Szymona K; Morylowska-Topolska J; Urbańska A; Krukow P; Kandefer-Szerszeń M; Zdzisińska B; Urbańska EM; Karakuła-Juchnowicz H
    Pol Merkur Lekarski; 2016 Sep; 41(243):160-164. PubMed ID: 27755520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
    Crespo-Facorro B; Pérez-Iglesias R; Ramirez-Bonilla M; Martínez-García O; Llorca J; Luis Vázquez-Barquero J
    J Clin Psychiatry; 2006 Oct; 67(10):1511-21. PubMed ID: 17107241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).
    Davidson M; Galderisi S; Weiser M; Werbeloff N; Fleischhacker WW; Keefe RS; Boter H; Keet IP; Prelipceanu D; Rybakowski JK; Libiger J; Hummer M; Dollfus S; López-Ibor JJ; Hranov LG; Gaebel W; Peuskens J; Lindefors N; Riecher-Rössler A; Kahn RS
    Am J Psychiatry; 2009 Jun; 166(6):675-82. PubMed ID: 19369319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Kynurenines in pathogenesis of endogenous psychiatric disorders].
    Shilov IuE; Bezrukov MV
    Vestn Ross Akad Med Nauk; 2013; (1):35-41. PubMed ID: 23805637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between purine metabolites and clinical symptoms in schizophrenia.
    Yao JK; Condray R; Dougherty GG; Keshavan MS; Montrose DM; Matson WR; McEvoy J; Kaddurah-Daouk R; Reddy RD
    PLoS One; 2012; 7(8):e42165. PubMed ID: 22916123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kynurenine and its metabolites in Alzheimer's disease patients.
    Gulaj E; Pawlak K; Bien B; Pawlak D
    Adv Med Sci; 2010; 55(2):204-11. PubMed ID: 20639188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients.
    Kim YK; Myint AM; Verkerk R; Scharpe S; Steinbusch H; Leonard B
    Neuropsychobiology; 2009; 59(2):123-9. PubMed ID: 19390223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.